Technology evaluation: Valspodar, Novartis AG

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 4, 2000, Pages 459-467

  Tai, H L ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIRICODAR; CYCLOSPORIN A; CYTARABINE; CYTOCHROME P450 3A; DEXAMETHASONE; DOXORUBICIN; ELACRIDAR; ERYTHROMYCIN; MEVINOLIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; TERFENADINE; VALSPODAR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CEREBELLAR ATAXIA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; HUMAN; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SOLID TUMOR; TREATMENT INDICATION;

BIOTECHNOLOGY; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MULTIPLE MYELOMA; OVARIAN NEOPLASMS; P-GLYCOPROTEIN;

ATAXIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0033836063     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives
2. Restoration of Taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ-PSC-833 and the cyclopeptolide SDZ-280-446
3. SDZ-PSC-833, a non-immunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia
4. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ-PSC-833
5. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ-PSC-833, a non-immunosuppressive cyclosporin derivative
6. SDZ-PSC-833 and SDZ-280-446 are the most active of various resistance-modifying agents In restoring rhodamine-123 retention within multidrug-resistant P388 cells
7. Pharmacological interactions between the resistance-modifying cyclosporine SDZ-PSC-833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity
8. Phase I study of etoposide with SDZ-PSC-833 as a modulator of multidrug resistance in patients with cancer
9. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay
10. The reversal of multidrug resistance in multicellular tumor spheroids by SDZ-PSC-833
11. Reversal of multidrug resistance by SDZ-PSC-833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study
12. Dose-dependent brain penetration of SDZ-PSC-833, a novel multidrug resistance-reversing cyclosporin, In rats
13. Cyclosporin A and PSC-833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line
14. Novartis: Interim data of investigational therapy shows potential of multidrug resistance compound in advanced ovarian cancer patients
15. Novartis: Novartis insulin secretalogue starlix on track for 1998 NDA, firm tells analysts Phase III under way for MDR tumor agent PSC-833 in three cancer types
16. SDZ-PSC-833/paclitaxel refractory ovarian carcinoma: A phase II trial with renewed responses
17. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF-120918 in multidrug-resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
18. A phase I/II trial of ONCEP chemotherapy with the multidrug resistance (MDR) modulator PSC-833 in patients with recurrent or refractory non-Hodgkin's lymphoma
19. Approaches to multidrug resistance reversal
20. Phase II study of PSC 833 (PSC) and VAD chemotherapy in patients with VAD-refractory multiple myeloma (MM)
21. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of cancer and leukemia group B study 9420
22. Valspodar: Current status and perspectives
23. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin
24. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
25. Decrease in kidney calbindin-D 28 kDa as a possible mechanism mediating cyclosporin A- and FK-506-induced calciurla and tubular mineralization
26. Comparative study on reversal efficacy of SDZ-VALSPODAR, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo
27. Characterization of P-glycoprotein transport and inhibition in vivo
28. 99mTc-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer
29. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analog SDZ-PSC-833
30. Availability of PSC-833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum
31. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane
32. Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations
33. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC-83 treatment
34. Optimizing the absorption of valspodar, a P-glycoprotein modulator, part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics
35. Optimizing the absorption of valspodar, a P-glycoprotein modulator, part II: Quantifying its pharmacokinetic variability and refining the bioavailabillty estimate
36. Effect of the mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ-PSC-833, a multidrug resistance-reversing agent, in mice
37. Role of lipoproteins in the plasma binding of SDZ-PSC-833, a novel multidrug resistance-reversing cyclosporin
38. The multidrug resistance modulator valspodar (PSC-833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite
39. Treatment of poor prognosis AML patients using PSC-833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
40. Clinical pharmacokinetics of doxorubicin in combination with GF-120918, a potent inhibitor of MDR1 P-glycoprotein